ArticleFrontiers in immunology2026
Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radical cystectomy remains a standard curative treatment for muscle-invasive bladder cancer (MIBC). Bladder preservation after systemic therapy without immediate surgery remains investigational and requires careful patient selection, rigorous reassessment, and structured surveillance. We report two cases of early tumor regression after limited-course immunotherapy-based systemic therapy, with bladder-intact survival during available follow-up. Case presentation: Two male patients aged 75 and 73 years with clinically staged bulky bladder tumors suspicious for MIBC (one cT3N0M0 and the other at least cT2N0M0) received limited-course PD-1 inhibitor-based systemic therapy without immediate radical cystectomy. Both patients showed marked regression after two treatment cycles: Case 1 received tislelizumab plus platinum-based chemotherapy, and Case 2 received toripalimab plus disitamab vedotin. In Case 2, post-treatment transurethral reassessment and multi-site biopsies showed no definite residual malignancy; one additional cycle was then administered. Radical cystectomy was recommended but declined in both cases. At approximately three years after treatment initiation, no clinically detectable recurrence was identified based on available, non-protocolized assessments, although interval cystoscopic surveillance was incomplete. Conclusion: These cases document unusually early regression after limited-course immunotherapy-based systemic therapy in clinically staged bulky bladder tumors. The findings remain hypothesis-generating and do not justify routine omission of radical cystectomy or abbreviated systemic therapy. Instead, they suggest that early response kinetics may identify exceptional responders who warrant rigorous multimodal reassessment, molecular characterization, and structured surveillance within future response-adapted bladder-preserving strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.